NR4A1 and glioblastoma: As another example, querying DLAD4U using Abemaciclib, an FDA-approved drug for hormone receptor–positive, human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer, revealed its potential effectiveness in glioblastoma [21].